{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:38Z","timestamp":1789471958139,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.trsl.2012.01.003","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T18:14:09Z","timestamp":1327947249000},"page":"265-276","source":"Crossref","is-referenced-by-count":22,"title":["Developing and assessing cardiovascular biomarkers"],"prefix":"10.1016","volume":"159","author":[{"given":"Razvan T.","family":"Dadu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2012.01.003_bib1","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1161\/CIRCULATIONAHA.105.598987","article-title":"Vascular biomarkers and surrogates in cardiovascular disease","volume":"113","author":"Tardif","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s00268-006-0712-2","article-title":"Role of biomarkers in developing new therapies for vascular disease","volume":"31","author":"Nambi","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.trsl.2012.01.003_bib3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/pr0501259","article-title":"So, you want to look for biomarkers","volume":"4","author":"LaBaer","year":"2005","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2012.01.003_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","article-title":"Biomarkers of cardiovascular disease: molecular basis and practical considerations","volume":"113","author":"Vasan","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1525-1497.1999.00283.x","article-title":"Exercise testing to predict outcome in patients with angina","volume":"14","author":"Hlatky","year":"1999","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association","volume":"119","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.trsl.2012.01.003_bib8","first-page":"199","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"30","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1373\/clinchem.2007.096529","article-title":"Statistical evaluation of prognostic vs diagnostic models: beyond the ROC curve","volume":"54","author":"Cook","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.trsl.2012.01.003_bib10","series-title":"Clinical measurement in drug evaluation","first-page":"3","article-title":"regulatory authority\u2019s opinion about surrogate endpoints","author":"Temple","year":"1995"},{"key":"10.1016\/j.trsl.2012.01.003_bib11","first-page":"439","article-title":"High-sensitivity C-reactive protein: clinical importance","volume":"29","author":"Bassuk","year":"2004","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib12","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1161\/01.CIR.102.18.2165","article-title":"Direct proinflammatory effect of C-reactive protein on human endothelial cells","volume":"102","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/01.CIR.103.21.2531","article-title":"Modulation of C-reactive protein\u2013mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs","volume":"103","author":"Pasceri","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib14","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/01.CIR.0000015126.83143.B4","article-title":"Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein","volume":"105","author":"Verma","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.CIR.0000052617.91920.FD","article-title":"C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis","volume":"107","author":"Devaraj","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/01.CIR.0000033116.22237.F9","article-title":"Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells","volume":"106","author":"Venugopal","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.0000029802.88087.5E","article-title":"A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis","volume":"106","author":"Verma","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.CIR.103.9.1194","article-title":"C-reactive protein\u2013mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis","volume":"103","author":"Zwaka","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1373\/clinchem.2008.119214","article-title":"C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease","volume":"55","author":"Ridker","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.trsl.2012.01.003_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive\u00a0protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib25","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib26","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.jacc.2009.10.006","article-title":"Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study","volume":"54","author":"Yang","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijcard.2007.11.085","article-title":"C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study","volume":"132","author":"Tohidi","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00008483-200609000-00009","article-title":"The relationship between C-reactive protein and other cardiovascular risk factors in men and women","volume":"26","author":"Arena","year":"2006","journal-title":"J Cardiopulm Rehabil"},{"key":"10.1016\/j.trsl.2012.01.003_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2796.2005.01563.x","article-title":"Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: the Cardiovascular Risk in Young Finns Study","volume":"258","author":"Raitakari","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.ijo.0802713","article-title":"Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults","volume":"28","author":"Williams","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.trsl.2012.01.003_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2012.01.003_bib32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2012.01.003_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/01.CIR.0000032135.98011.C4","article-title":"C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study","volume":"106","author":"Wang","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0735-1097(00)00680-X","article-title":"Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening","volume":"36","author":"Redberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib35","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1161\/STROKEAHA.106.476135","article-title":"High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the Carotid Atherosclerosis Progression Study","volume":"38","author":"Lorenz","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.trsl.2012.01.003_bib36","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/01.STR.0000181740.74005.ee","article-title":"The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population","volume":"36","author":"Makita","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.trsl.2012.01.003_bib37","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archinte.166.13.1368","article-title":"An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study","volume":"166","author":"Folsom","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib38","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib39","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/01.CIR.0000120707.98922.E3","article-title":"C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany","volume":"109","author":"Koenig","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib40","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.jacc.2010.09.002","article-title":"2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"56","author":"Greenland","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-151-7-200910060-00008","article-title":"Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement","volume":"151","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCULATIONAHA.110.948570","article-title":"Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels","volume":"123","author":"Dehghan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2012.01.003_bib44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.trsl.2012.01.003_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11883-010-0095-6","article-title":"Lp-PLA2 as a marker of cardiovascular diseases","volume":"12","author":"Bhatti","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.trsl.2012.01.003_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.ATV.0000196545.32393.13","article-title":"Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions","volume":"26","author":"Iribarren","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl III","key":"10.1016\/j.trsl.2012.01.003_bib47","article-title":"Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk","volume":"110","author":"Wolfert","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cll.2006.06.003","article-title":"Lipoprotein-associated phospholipase A2","volume":"26","author":"McConnell","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib49","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","article-title":"Lipoprotein-associated\u00a0phospholipase A2 as an independent predictor of coronary heart disease","volume":"343","author":"Packard","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated\u00a0phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0025-6196(11)60992-0","article-title":"Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review","volume":"82","author":"Garza","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.trsl.2012.01.003_bib52","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1161\/01.CIR.0000143377.53389.C8","article-title":"Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany","volume":"110","author":"Koenig","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.CIR.0000154553.12214.CD","article-title":"Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study","volume":"111","author":"Oei","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib54","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/hrt.2009.170134","article-title":"Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk Prospective Population Study","volume":"95","author":"Rana","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.trsl.2012.01.003_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/STROKEAHA.107.513259","article-title":"Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study","volume":"40","author":"Nambi","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.trsl.2012.01.003_bib56","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/ATVBAHA.107.142679","article-title":"Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects","volume":"27","author":"Persson","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2012.01.003_bib57","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1373\/clinchem.2007.086298","volume":"53","author":"Winkler","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.trsl.2012.01.003_bib58","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.ATV.0000240406.89440.0c","article-title":"Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community","volume":"26","author":"Gerber","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2012.01.003_bib59","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00392-007-0540-x","article-title":"Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach. The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II)","volume":"96","author":"Mockel","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib60","doi-asserted-by":"crossref","first-page":"41F","DOI":"10.1016\/j.amjcard.2008.04.018","article-title":"Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker","volume":"101","author":"Corson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib61","article-title":"Genome-wide association study of Lp-PLA2 activity and mass in the Framingham Heart Study","volume":"4","author":"Suchindran","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1016\/j.trsl.2012.01.003_bib62","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/eurheartj\/ehr372","article-title":"Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies","volume":"33","author":"Grallert","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trsl.2012.01.003_bib63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1471-4892(01)00024-8","article-title":"Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target","volume":"1","author":"MacPhee","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.trsl.2012.01.003_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0960-894X(01)00678-3","article-title":"Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones","volume":"12","author":"Boyd","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.trsl.2012.01.003_bib65","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib66","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ahj.2009.09.017","article-title":"Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome","volume":"158","author":"Schwartz","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.trsl.2012.01.003_bib67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ahj.2010.06.010","article-title":"Novel biomarkers in cardiovascular disease: update 2010","volume":"160","author":"Hochholzer","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.trsl.2012.01.003_bib68","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1172\/JCI5549","article-title":"Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in\u00a0vitro","volume":"103","author":"Podrez","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2012.01.003_bib69","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/01.CIR.0000042674.89762.20","article-title":"Neutrophil infiltration of culprit lesions in acute coronary syndromes","volume":"106","author":"Naruko","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJMoa012295","article-title":"Widespread coronary inflammation in unstable angina","volume":"347","author":"Buffon","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib71","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0002-9440(10)64036-9","article-title":"Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes","volume":"158","author":"Sugiyama","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2012.01.003_bib72","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1001\/jama.286.17.2136","article-title":"Association between myeloperoxidase levels and risk of coronary artery disease","volume":"286","author":"Zhang","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2012.01.003_bib73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2007.03.033","article-title":"Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study","volume":"50","author":"Meuwese","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib74","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.0000090690.67322.51","article-title":"Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes","volume":"208","author":"Baldus","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib75","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa035003","article-title":"Prognostic value of myeloperoxidase in patients with chest pain","volume":"209","author":"Brennan","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib76","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jacc.2009.11.050","article-title":"Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography","volume":"55","author":"Heslop","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib77","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1152\/japplphysiol.01292.2005","article-title":"Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors","volume":"100","author":"Roberts","year":"2006","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib78","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0002-9149(91)90466-X","article-title":"Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction","volume":"67","author":"Katus","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib79","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/clinchem\/44.9.1919","article-title":"Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim","volume":"44","author":"Ricchiuti","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.trsl.2012.01.003_bib80","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib81","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1161\/CIRCULATIONAHA.105.609974","article-title":"Prevalence and determinants of troponin T elevation in the general population","volume":"113","author":"Wallace","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib82","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/01.CIR.93.9.1651","article-title":"Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease","volume":"93","author":"Lindahl","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib83","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2008.04.033","article-title":"Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study","volume":"52","author":"Daniels","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib84","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/CIRCULATIONAHA.107.708529","article-title":"Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality","volume":"116","author":"Eggers","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib85","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCULATIONAHA.106.655076","article-title":"Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure","volume":"116","author":"Latini","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib86","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMoa0805299","article-title":"A sensitive cardiac troponin T assay in stable coronary artery disease","volume":"361","author":"Omland","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib87","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.2010.1768","article-title":"Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population","volume":"304","author":"de Lemos","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2012.01.003_bib88","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1001\/jama.2010.1708","article-title":"Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults","volume":"304","author":"deFilippi","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2012.01.003_bib89","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/CIRCULATIONAHA.110.005264","article-title":"Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study","volume":"123","author":"Saunders","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/01.CIR.90.1.195","article-title":"Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure","volume":"90","author":"Yasue","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib91","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0002-8703(98)70054-7","article-title":"Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease","volume":"135","author":"Stein","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.trsl.2012.01.003_bib92","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/hrt.76.3.232","article-title":"Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment","volume":"76","author":"Omland","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.trsl.2012.01.003_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib94","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib95","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1161\/CIRCULATIONAHA.107.182882","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes","volume":"115","author":"Morrow","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b787","article-title":"Natriuretic peptides in elderly people with acute myocardial infarction","volume":"338","author":"Ribeiro","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.trsl.2012.01.003_bib97","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jacc.2007.03.038","article-title":"Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial","volume":"50","author":"Omland","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.01.003_bib98","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib99","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa011053","article-title":"The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes","volume":"345","author":"de Lemos","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.01.003_bib100","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.109.884866","article-title":"B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies","volume":"120","author":"Angelantonio","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.01.003_bib101","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.HYP.0000216794.24161.8c","article-title":"Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure","volume":"47","author":"McKie","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.trsl.2012.01.003_bib102","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/HJH.0b013e3282f18301","article-title":"Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex","volume":"26","author":"Olsen","year":"2008","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.trsl.2012.01.003_bib103","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/jama.293.13.1609","article-title":"N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults","volume":"293","author":"Kistorp","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2012.01.003_bib104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/heart.86.1.21","article-title":"Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population","volume":"86","author":"McDonagh","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.trsl.2012.01.003_bib105","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/eurheartj\/ehi878","article-title":"Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men","volume":"27","author":"Laukkanen","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trsl.2012.01.003_bib106","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/CIRCULATIONAHA.105.590927","article-title":"Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study","volume":"114","author":"Blankenberg","year":"2006","journal-title":"Circulation"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524412000047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524412000047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T11:40:21Z","timestamp":1593603621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524412000047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1931524412000047"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2012.01.003","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}